1. Home
  2. INMD vs ABUS Comparison

INMD vs ABUS Comparison

Compare INMD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InMode Ltd.

INMD

InMode Ltd.

HOLD

Current Price

$13.92

Market Cap

842.0M

Sector

Health Care

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.56

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INMD
ABUS
Founded
2008
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
842.0M
848.8M
IPO Year
2018
2008

Fundamental Metrics

Financial Performance
Metric
INMD
ABUS
Price
$13.92
$4.56
Analyst Decision
Hold
Strong Buy
Analyst Count
5
1
Target Price
$17.33
$5.00
AVG Volume (30 Days)
919.7K
1.2M
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$1.74
N/A
Revenue Next Year
$3.26
$239.71
P/E Ratio
$10.11
$5.28
Revenue Growth
N/A
128.21
52 Week Low
$12.72
$3.04
52 Week High
$16.74
$5.10

Technical Indicators

Market Signals
Indicator
INMD
ABUS
Relative Strength Index (RSI) 48.25 57.10
Support Level $13.71 $4.16
Resistance Level $14.70 $4.60
Average True Range (ATR) 0.28 0.18
MACD -0.01 0.04
Stochastic Oscillator 51.49 67.81

Price Performance

Historical Comparison
INMD
ABUS

About INMD InMode Ltd.

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: